Skip to main content

Advertisement

SpringerLink
Log in

A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Paclitaxel, when combined with carboplatin, exhibits a platelet-sparing effect. Paclitaxel is formulated in Cremophor EL (CrEL), which has been shown in preclinical models to reduce haematological toxicity from radiotherapy and chemotherapy. We sought to determine the effect of a 3-h infusion of 20 ml/m2 (equivalent to 175 mg/m2 paclitaxel) CrEL on myelosuppression following carboplatin chemotherapy, and the effect of CrEL on carboplatin pharmacokinetics.

Methods

A total of 16 patients with locally advanced or metastatic cancer were randomized to receive either CrEL or saline over 3 h prior to carboplatin (area under the curve, AUC, 5–7). Each patient was subsequently crossed over to the other treatment. Blood samples were collected at selected time-points for estimation of platinum AUC and 24-h platinum levels. Full blood counts were obtained three times per week.

Results

Of the 16 patients randomized, 15 were evaluable. Myelosuppression was measured by percentage fall at nadir and nadir levels. No significant differences were obtained when comparing CrEL and saline with respect to the above end-points after adjusting for multiple testing. There was no evidence to indicate that CrEL altered the pharmacokinetics of carboplatin.

Conclusion

CrEL at this dose and schedule does not appear to be a major contributory factor to the platelet-sparing effect of paclitaxel when combined with carboplatin, nor does it alter the pharmacokinetics of carboplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Badary OA, Abdel-Naim AB, Khalifa AE, Hamada FM (2000) Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL. Naunyn Schmiedebergs Arch Pharmacol 361:339

    Article  CAS  PubMed  Google Scholar 

  2. Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ (1999) Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 17:676

    CAS  PubMed  Google Scholar 

  3. Bertoncello I, Kriegler AB, Woodcock DM, Williams B, Barber L, Nilsson SK (1995) Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil. Int J Radiat Biol 67:57

    CAS  PubMed  Google Scholar 

  4. Blommaert FA, van Dijk-Knijnenburg HC, Dijt FJ, den Engelse L, Baan RA, Berends F, Fichtinger-Schepman AM (1995) Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 34:8474

    CAS  PubMed  Google Scholar 

  5. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748

    CAS  PubMed  Google Scholar 

  6. Eschalier A, Lavarenne J, Burtin C, Renoux M, Chapuy E, Rodriguez M (1988) Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 21:246

    CAS  PubMed  Google Scholar 

  7. Fujiwara K, Yamauchi H, Suzuki S, Ishikawa H, Tanaka Y, Fujiwara M, Kohno I (2001) The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. Cancer Chemother Pharmacol 47:22

    Article  CAS  PubMed  Google Scholar 

  8. Gelderblom H, Sparreboom A, de Jonge MJ, Loos WJ, Wilms E, Mantel MA, Hennis B, Camlett I, Verweij J, van der Burg ME (2001) Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer. Br J Cancer 85:1124

    Article  CAS  PubMed  Google Scholar 

  9. Gelderblom H, Loos WJ, Verweij J, van der Burg ME, de Jonge MJ, Brouwer E, Nooter K, Stoter G, Sparreboom A (2002) Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies. Eur J Cancer 38:205

    Article  CAS  PubMed  Google Scholar 

  10. de Graaff M, Maliepaard M, Pluim D, Floot BJ, Slaper-Cortenbach IC, Schellens JH (1999) In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM. Anticancer Drugs 10:213

    PubMed  Google Scholar 

  11. Guminski AD, Harnett PR, deFazio A (2001) Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line—a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemother Pharmacol 48:229

    Article  CAS  PubMed  Google Scholar 

  12. Isla D, Rosell R, Sanchez JJ, Carrato A, Felip E, Camps C, Artal A, Gonzalez-Larriba JL, Azagra P, Alberola V, Martin C, Massuti B (2001) Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 19:1071

    CAS  PubMed  Google Scholar 

  13. Kenward MG, Jones B (1987) The analysis of data from 2×2 cross-over trials with baseline measurements. Stat Med 6:911

    CAS  PubMed  Google Scholar 

  14. Kris MG, O’Connell JP, Gralla RJ, Wertheim MS, Parente RM, Schiff PB, Young CW (1986) Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 70:605

    CAS  PubMed  Google Scholar 

  15. Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJ, van Groeningen CJ, Postmus PE, Pinedo HM, Peters GJ (1999) Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17:2190

    CAS  PubMed  Google Scholar 

  16. Millward MJ, Webster LK, Toner GC, Bishop JF, Rischin D, Stokes KH, Johnston VK, Hicks R (1996) Carboplatin dosing based on measurement of renal function—experience at the Peter MacCallum Cancer Institute. Aust N Z J Med 26:372

    CAS  PubMed  Google Scholar 

  17. O’Shaughnessy JNS, Albain K (2003) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study. Proc Am Soc Clin Oncol Chicago 7

  18. Pertusini E, Ratajczak J, Majka M, Vaughn D, Ratajczak MZ, Gewirtz AM (2001) Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood 97:638

    Article  CAS  PubMed  Google Scholar 

  19. Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U (2003) Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 95:1118

    Article  CAS  PubMed  Google Scholar 

  20. Rinaldi DA, Lormand NA, Brierre JE, Cole JL, Stagg MP, Fontenot MF, Buller EJ, Rainey JM (2002) Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2). Am J Clin Oncol 25:523

    Article  PubMed  Google Scholar 

  21. Rischin D, Webster LK, Millward MJ, Linahan BM, Toner GC, Woollett AM, Morton CG, Bishop JF (1996) Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 88:1297

    CAS  PubMed  Google Scholar 

  22. Scialli AR, DeSesso JM, Rahman A, Husain SR, Goeringer GC (1995) Embryotoxicity of free and liposome-encapsulated taxol in the chick. Pharmacology 51:145

    CAS  PubMed  Google Scholar 

  23. Shord SS, Faucette SR, Gillenwater HH, Pescatore SL, Hawke RL, Socinski MA, Lindley C (2003) Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51:328

    CAS  PubMed  Google Scholar 

  24. Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Vigano L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L (1998) Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4:1937

    CAS  PubMed  Google Scholar 

  25. de Vos AI, Nooter K, Verweij J, Loos WJ, Brouwer E, de Bruijn P, Ruijgrok EJ, van der Burg ME, Stoter G, Sparreboom A (1997) Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. Ann Oncol 8:1145

    Article  PubMed  Google Scholar 

  26. Wagner JG (1993) Pharmacokinetics for the pharmaceutical scientist. Technomic, Lancaster, PA

  27. Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, Bertoncello I (1990) Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50:4199

    CAS  PubMed  Google Scholar 

  28. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH (1992) Reversal of multidrug resistance by surfactants. Br J Cancer 66:62

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are grateful for the conscientious sample collection by nursing staff at Peter MacCallum Cancer Centre.

Author information

Author notes

  1. Michael J. Millward

    Present address: Sir Charles Gairdner Hospital, Perth, WA, Australia

  2. Lorraine K. Webster

    Present address: Mayne Pharma, Melbourne, Victoria, Australia

Authors and Affiliations

  1. Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

    Sherene Loi, Danny Rischin, Michael Michael & Michael J. Millward

  2. Statistical Centre, Peter MacCallum Cancer Centre, Melbourne, Australia

    Kally Yuen

  3. Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, Melbourne, Australia

    Kerrie H. Stokes, Andrew G. Ellis & Lorraine K. Webster

Authors
  1. Sherene Loi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danny Rischin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Michael
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kally Yuen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kerrie H. Stokes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrew G. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michael J. Millward
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lorraine K. Webster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Danny Rischin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loi, S., Rischin, D., Michael, M. et al. A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy. Cancer Chemother Pharmacol 54, 407–414 (2004). https://doi.org/10.1007/s00280-004-0792-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0792-3

Keywords

Search

Navigation